Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
Prelude Therapeutics, a clinical-stage precision oncology company, has recently announced multiple clinical and preclinical posters at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference, also known as the Triple Meeting, took place from October 11-15, 2023, at the Hynes Convention Center in Boston, MA.
The four poster presentations by Prelude Therapeutics included data from two ongoing Phase 1 clinical trials for their CDK9 inhibitor, PRT2527, and CDK4/6 inhibitor, PRT3645. Additionally, two preclinical posters showcased their SMARCA2 degrader compound, PRT3789.
Dr. Jane Huang, President and Chief Medical Officer of Prelude Therapeutics, expressed her excitement about the additional data from their solid tumor trial investigating PRT2527. The data continues to support the molecule’s best-in-class safety and target engagement profile. She also mentioned a second Phase 1 clinical trial in patients with hematological cancers, with initial data expected in the first half of 2024.
Furthermore, Dr. Huang presented the initial clinical data for PRT3645, a differentiated brain and tissue penetrant next-generation CDK4/6 inhibitor. The data demonstrated a generally well-tolerated safety profile and high target inhibition, reaching levels needed for efficacy in preclinical studies.
In addition to their clinical presentations, Prelude Therapeutics highlighted the potential of their SMARCA2 degrader compound, PRT3789. Dr. Peggy Sherle, Chief Scientific Officer of Prelude Therapeutics, mentioned the preclinical efficacy of PRT3789 as monotherapy. She also emphasized the added potential of combining it with immunotherapies, chemotherapy, and targeted therapies such as KRAS inhibitors. The company has developed sensitive and quantitative assays to measure SMARCA2 degradation in preclinical models, enabling them to assess target engagement in the clinic. Clinical readouts for PRT3789 are planned for 2024.
Prelude Therapeutics is a clinical-stage precision oncology company dedicated to developing innovative drug candidates targeting critical cancer cell pathways. Their pipeline consists of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with underserved patients.
The company’s current clinical candidates include PRT1419, a potent and selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789, an IV administered, potent and highly selective SMARCA2 degrader. They also have a preclinical oral candidate targeting SMARCA2.
Prelude Therapeutics remains committed to advancing their product candidates through discovery, preclinical, and clinical development. While the timing and results of biotechnology development and regulatory approval are inherently uncertain, the company is optimistic about the potential benefits their product candidates can bring to patients in need.
For more information about Prelude Therapeutics and their innovative oncology pipeline, visit their website and follow them on LinkedIn.